The US Food and Drug Administration (FDA) has cleared Archeus Technologies’ Investigational New Drug (IND) application for ART-101, a novel receptor-based targeting small molecule for the imaging and treatment of prostate cancer. This clearance enables the company to initiate a Phase I clinical trial in men with metastatic castration-resistant prostate… Read More
In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business. In this episode, Megan Thomas is in conversation with Professor Jonathan… Read More
The latest new trial data presented at the 30th European Hematology Association (EHA) 2025 Congress. Bispecific antibody for diffuse large B-cell lymphoma Genmab shared new results from the Phase Ib/II EPCORE NHL-2 trial Arm 10 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously,… Read More
Treating advanced anal cancer patients with both immunotherapy and chemotherapy improved overall survival by an average of six months, according to a study led by The Royal Marsden NHS Foundation Trust. Patients with advanced squamous cell anal carcinoma (SCAC) are usually treated with chemotherapy. Results… Read More
Scientists at The Institute of Cancer Research (ICR), London, have discovered what may cause some treatments to stop working in people living with bowel cancer. The findings could help researchers use information about a person’s cancer to make better use of current treatments and develop more targeted… Read More
This year’s American Society of Clinical Oncology (ASCO) Annual Meeting took place at the McCormick Place Convention Center in Chicago from 30 May to 3 June 2025. DDW’s Megan Thomas collected commentary from industry experts in attendance. CCR8 therapies gain clinical significance Stephan Schann is Chief Scientific Officer at Domain… Read More
Research published in the journal Blood shows that the drug tazemetostat could work better when combined with another targeted drug. For patients with follicular lymphoma, treatment can include the drug tazemetostat – but patients have varying responses, and some see their cancer… Read More
A clinical trial for early-stage breast cancer patients with BRCA gene mutations has reported 100% survival after three years. In a Phase III trial, Cancer Research UK researchers stopped BRCA-linked breast cancers growing or coming back by giving patients olaparib tablets 48 hours after each chemotherapy dose. … Read More
The Wellcome Sanger Institute, Parse Biosciences, and the Computational Health Center at Helmholtz Munich has announced a collaboration to build the foundation of a single cell atlas, focused on understanding and elucidating cancer plasticity in response to therapies. The collaboration will catalyse an ambitious future phase to… Read More
Parabilis has achieved the first pharmacological proof-of-concept for degrading the long-considered ‘undruggable’ transcription factor ERG in prostate cancer. DDW’s Megan Thomas speaks with Dr Jonathan Hurov, Executive Vice President, Discovery Biology at Parabilis Medicines, about the milestone. MT: ERG has been considered ‘undruggable’ for decades. Why is this? JH: ERG… Read More
Scientists at the National Institute of Standards and Technology (NIST) have developed the first US standard for measuring the radioactivity of actinium-225, a radioactive isotope that drug companies are using to develop a new class of anticancer drugs. The new standard, which is tied to the International… Read More
Perspective Therapeutics has shared interim results from its ongoing Phase I/IIa clinical trial of [212Pb]VMT-α-NET at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The Phase I/IIa clinical trial is a multi-centre open-label dose escalation and dose expansion study of [212Pb]VMT-α-NET in patients with unresectable… Read More
Results of a global study presented at the American Society of Clinical Oncology (ASCO) annual meeting have shown that camizestrant for advanced breast cancer can be used to treat emerging tumours. The study was funded by AstraZeneca and co-led by researchers at The Institute of Cancer Research,… Read More
The START Center for Cancer Research (START) and OneOncology has announced a strategic partnership to launch early phase clinical trial sites. The rollout includes the Los Angeles Cancer Network (LACN, California), The Center for Cancer and Blood Disorders (CCBD, Texas), and Astera Cancer Care (New Jersey). This arrangement builds on… Read More
A drug discovery company co-founded by researchers at the University of Dundee and the University of Arizona has received $4 million in venture funding. Branch Therapeutics, founded in November 2024, is a preclinical stage company seeking to develop drugs that are orally bioavailable, well-tolerated, and can treat multiple cancer types. … Read More
In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business. In this episode, Megan Thomas is in conversation with Phil L’Huillier, CEO of… Read More
